CHRNG

Summary

CHRNG (cholinergic receptor nicotinic gamma subunit, HGNC:1967) is a protein-coding gene on chromosome 2q37.1, encoding Acetylcholine receptor subunit gamma (P07510). After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

The mammalian muscle-type acetylcholine receptor is a transmembrane pentameric glycoprotein with two alpha subunits, one beta, one delta, and one epsilon (in adult skeletal muscle) or gamma (in fetal and denervated muscle) subunit. This gene, which encodes the gamma subunit, is expressed prior to the thirty-third week of gestation in humans. The gamma subunit of the acetylcholine receptor plays a role in neuromuscular organogenesis and ligand binding and disruption of gamma subunit expression prevents the correct localization of the receptor in cell membranes. Mutations in this gene cause Escobar syndrome and a lethal form of multiple pterygium syndrome. Muscle-type acetylcholine receptor is the major antigen in the autoimmune disease myasthenia gravis.

Source: NCBI Gene 1146 — RefSeq curated summary.

At a glance

• Gene–disease (curated): CHRNG-associated hypo-akinesia disorder of prenatal onset (Definitive, ClinGen) — +3 more curated relationships
• GWAS associations: 2
• Clinical variants (ClinVar): 542 total — 36 pathogenic, 33 likely-pathogenic (top 6% of genes corpus-wide)
• GTEx eGene: eQTL in 2 tissues, sQTL in 1 (q < 0.05)
• Phenotypes (HPO): 122
• Drug target: yes — 14 via a complex or family; 10 molecules with ChEMBL bioactivity (top 3% of genes corpus-wide)
• Approved drugs acting on a complex or family including it: 14 — Atracurium Besylate, Cisatracurium Besylate, Decamethonium Bromide, +11 more (Muscle-type nicotinic acetylcholine receptor)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.29 (unconstrained)
• MANE Select transcript: NM_005199

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1967
Approved symbol	CHRNG
Name	cholinergic receptor nicotinic gamma subunit
Location	2q37.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000196811
Ensembl biotype	protein_coding
OMIM	100730
Entrez	1146

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron

MANE Select: ENST00000651502

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2

ENST00000651502, ENST00000389492, ENST00000485094

RefSeq mRNA: 1 — MANE Select: NM_005199 NM_005199

CCDS: CCDS33400

Canonical transcript exons

ENST00000651502 — 12 exons

Exon	Start	End
ENSE00000922599	232541374	232541529
ENSE00000922600	232542423	232542520
ENSE00000922601	232542882	232543082
ENSE00000922602	232543275	232543389
ENSE00000922604	232544367	232544580
ENSE00000922605	232544772	232544902
ENSE00001506031	232543585	232543699
ENSE00003487420	232540602	232540711
ENSE00003524326	232539992	232540131
ENSE00003650506	232540381	232540425
ENSE00003843733	232539692	232539802
ENSE00003845666	232545543	232548115

Expression profiles

Bgee: expression breadth broad, 54 present calls, max score 86.22.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.0970 / max 178.8929, expressed in 109 samples.

Highest expression (Bgee): pancreatic ductal cell, gastrocnemius, muscle of leg, hindlimb stylopod muscle, muscle organ.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CHRNG is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 2 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

3 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Muscle Skeletal	eqtl	4.1e-55	+0.54	2:232537797:C:T
Muscle Skeletal	sqtl	4.1e-18	+0.61	2:232537797:C:T
Minor Salivary Gland	eqtl	2.1e-02	-0.31	2:232504907:C:A

FANTOM5 promoters

3 alternative TSS:

Promoter ID	TPM avg	Samples expressed
25992	0.5045	67
25994	0.4026	86
25993	0.1899	58

Top tissues by expression

showing 100 of 200 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	86.22	silver quality
gastrocnemius	UBERON:0001388	84.84	gold quality
muscle of leg	UBERON:0001383	83.14	gold quality
hindlimb stylopod muscle	UBERON:0004252	78.28	gold quality
muscle organ	UBERON:0001630	77.57	gold quality
endothelial cell	CL:0000115	73.66	silver quality
epithelial cell of pancreas	CL:0000083	72.58	gold quality
cervix epithelium	UBERON:0004801	72.57	gold quality
cervix squamous epithelium	UBERON:0006922	72.32	gold quality
pharyngeal mucosa	UBERON:0000355	72.20	silver quality
body of tongue	UBERON:0011876	71.87	gold quality
cerebellar vermis	UBERON:0004720	70.62	silver quality
cardia of stomach	UBERON:0001162	70.43	gold quality
gluteal muscle	UBERON:0002000	70.41	silver quality
synovial joint	UBERON:0002217	70.39	silver quality
vena cava	UBERON:0004087	70.35	gold quality
subthalamic nucleus	UBERON:0001906	69.94	gold quality
inferior vagus X ganglion	UBERON:0005363	69.88	gold quality
pericardium	UBERON:0002407	69.80	gold quality
substantia nigra pars reticulata	UBERON:0001966	69.71	gold quality
ventral tegmental area	UBERON:0002691	69.65	gold quality
lateral globus pallidus	UBERON:0002476	69.60	gold quality
pons	UBERON:0000988	69.52	gold quality
lateral nuclear group of thalamus	UBERON:0002736	69.49	gold quality
dorsal plus ventral thalamus	UBERON:0001897	69.17	gold quality
penis	UBERON:0000989	68.87	silver quality
triceps brachii	UBERON:0001509	68.33	gold quality
periodontal ligament	UBERON:0008266	68.07	gold quality
mucosa of urinary bladder	UBERON:0001259	68.04	gold quality
skeletal muscle tissue	UBERON:0001134	66.87	gold quality
oviduct epithelium	UBERON:0004804	66.82	gold quality
thymus	UBERON:0002370	66.36	gold quality
layer of synovial tissue	UBERON:0007616	65.57	gold quality
deltoid	UBERON:0001476	65.44	silver quality
olfactory bulb	UBERON:0002264	65.44	gold quality
type B pancreatic cell	CL:0000169	64.45	gold quality
globus pallidus	UBERON:0001875	64.33	gold quality
tongue squamous epithelium	UBERON:0006919	63.75	gold quality
medial globus pallidus	UBERON:0002477	62.94	gold quality
epithelium of esophagus	UBERON:0001976	62.63	gold quality
muscle tissue	UBERON:0002385	62.55	gold quality
squamous epithelium	UBERON:0006914	62.47	gold quality
parotid gland	UBERON:0001831	62.37	gold quality
bone marrow cell	CL:0002092	61.90	gold quality
orbitofrontal cortex	UBERON:0004167	61.64	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	61.47	gold quality
Brodmann (1909) area 46	UBERON:0006483	61.08	gold quality
palpebral conjunctiva	UBERON:0001812	60.67	gold quality
esophagus squamous epithelium	UBERON:0006920	60.50	gold quality
quadriceps femoris	UBERON:0001377	60.43	gold quality
choroid plexus epithelium	UBERON:0003911	60.21	gold quality
decidua	UBERON:0002450	59.79	gold quality
vastus lateralis	UBERON:0001379	59.58	gold quality
epithelium of nasopharynx	UBERON:0001951	59.24	gold quality
oocyte	CL:0000023	58.83	gold quality
nasal cavity epithelium	UBERON:0005384	58.69	gold quality
myocardium	UBERON:0002349	58.67	gold quality
diaphragm	UBERON:0001103	58.60	gold quality
cartilage tissue	UBERON:0002418	58.12	gold quality
epithelium of mammary gland	UBERON:0003244	57.95	gold quality
middle temporal gyrus	UBERON:0002771	57.86	gold quality
oral cavity	UBERON:0000167	57.81	gold quality
Brodmann (1909) area 23	UBERON:0013554	57.78	gold quality
male germ cell	CL:0000015	57.76	gold quality
mammalian vulva	UBERON:0000997	57.59	gold quality
ileal mucosa	UBERON:0000331	57.43	silver quality
hair follicle	UBERON:0002073	57.42	gold quality
secondary oocyte	CL:0000655	57.22	gold quality
mammary duct	UBERON:0001765	57.18	gold quality
renal glomerulus	UBERON:0000074	57.15	gold quality
skin of hip	UBERON:0001554	57.04	silver quality
sperm	CL:0000019	56.75	gold quality
gingival epithelium	UBERON:0001949	56.48	gold quality
nephron tubule	UBERON:0001231	55.97	gold quality
metanephric glomerulus	UBERON:0004736	55.96	gold quality
sural nerve	UBERON:0015488	55.46	silver quality
tibia	UBERON:0000979	55.25	gold quality
mucosa of sigmoid colon	UBERON:0004993	55.15	gold quality
kidney epithelium	UBERON:0004819	55.06	gold quality
seminal vesicle	UBERON:0000998	54.92	silver quality
pleura	UBERON:0000977	54.73	gold quality
colonic mucosa	UBERON:0000317	54.39	gold quality
upper leg skin	UBERON:0004262	54.29	silver quality
buccal mucosa cell	CL:0002336	54.14	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	54.05	gold quality
parietal pleura	UBERON:0002400	53.92	gold quality
jejunum	UBERON:0002115	53.81	gold quality
visceral pleura	UBERON:0002401	53.55	gold quality
germinal epithelium of ovary	UBERON:0001304	53.08	gold quality
cranial nerve II	UBERON:0000941	52.44	silver quality
blood	UBERON:0000178	52.42	gold quality
placenta	UBERON:0001987	52.06	gold quality
postcentral gyrus	UBERON:0002581	51.67	gold quality
inferior olivary complex	UBERON:0002127	51.66	gold quality
bronchus	UBERON:0002185	51.55	gold quality
left ventricle myocardium	UBERON:0006566	51.35	gold quality
epithelium of bronchus	UBERON:0002031	50.89	gold quality
pigmented layer of retina	UBERON:0001782	50.48	gold quality
biceps brachii	UBERON:0001507	50.31	gold quality
adrenal tissue	UBERON:0018303	49.61	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	243.54
E-ANND-3	yes	3.22

HPA expression

RNA tissue specificity: Tissue enriched

40 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Skeletal muscle	tissue	19.6
Tongue	tissue	1.3
Nucleus accumbens	tissue	0.9
Hippocampus	tissue	0.9
Locus coeruleus	tissue	0.7
Basal ganglia	tissue	0.6
Choroid plexus	tissue	0.6
Postcentral gyrus	tissue	0.6
Olfactory bulb	tissue	0.6
Cerebral cortex	tissue	0.5
Putamen	tissue	0.5
Amygdala	tissue	0.5
Hypothalamus	tissue	0.5
Hippocampal formation	tissue	0.5
Entorhinal cortex	tissue	0.5
Periaqueductal gray	tissue	0.5
Septum	tissue	0.5
Insular cortex	tissue	0.5
Prefrontal cortex	tissue	0.4
Pons	tissue	0.4
Cerebellum	tissue	0.4
Substantia nigra	tissue	0.4
Thymus	tissue	0.4
Ventral forebrain	tissue	0.4
Temporal cortex	tissue	0.4
Epididymis	tissue	0.3
Motor cortex	tissue	0.3
Midbrain	tissue	0.3
Medulla oblongata	tissue	0.3
Thalamus	tissue	0.3
Superior colliculi	tissue	0.3
Spinal cord	tissue	0.3
Corpus callosum	tissue	0.3
Prostate	tissue	0.3
Retrosplenial and cingulate cortex	tissue	0.3
Somatosensory cortex	tissue	0.3
Retrosplenial cortex	tissue	0.3
Occipital cortex	tissue	0.3
Breast	tissue	0.1
Seminal vesicle	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 188; highest nTPM — Nucleus ambiguus (1.1), Orbitofrontal gyrus, anterior (1.1), Corticomedial amygdala (1.0), Piriform cortex (1.0), Arcuate nucleus (0.9).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYOD1, MYOG, TCF3

miRNA regulators (miRDB)

Targeting CHRNG by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 37 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-1251-3P	99.64	67.21	1408
HSA-MIR-6861-3P	99.60	68.46	444
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-5589-3P	99.29	68.30	1443
HSA-MIR-5693	99.24	66.67	1106
HSA-MIR-4758-3P	99.12	63.96	869
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-4774-3P	98.90	67.82	737
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-7114-3P	98.42	66.53	569
HSA-MIR-1262	98.17	66.52	757
HSA-MIR-1180-5P	98.16	65.32	460
HSA-MIR-4494	97.86	64.93	850
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-4432	97.80	67.87	705
HSA-MIR-4741	97.69	64.14	883
HSA-MIR-4675	97.69	64.82	774
HSA-MIR-510-5P	97.66	65.82	916
HSA-MIR-4678	97.59	68.31	902
HSA-MIR-3189-5P	97.55	66.71	655
HSA-MIR-5699-5P	97.36	67.03	1014

Functional genomics

gnomAD constraint: pLI 4.42e-25, LOEUF 1.29, missense Z 0.991 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000651502 — one region, missense o/e 0.94.

Literature-anchored findings (GeneRIF, showing 13)

• A good correlation was found between the expression of PAX3/7-FKHR and AChR, while MyoD1 was more sensitive but less specific. (PMID:16435141)
• CHRNG mutations identified in families with Escobar syndrome show that the trait is a congenital dysmorphology caused by transient inactivation of the neuromuscular endplate. (PMID:16826520)
• Mutations cxause lethal and nonlethal forms of multiple pterygium syndrome. (PMID:16826531)
• constructed and characterized four AChR gamma extracellular domain variants (PMID:18502212)
• This study suggests for the first time in humans, a possible role for genetic variation in the neuromuscular nicotinic acetylcholine receptor, particularly the gamma subunit, in systolic blood pressure regulation (PMID:18625075)
• Detection of PAX3/7-FKHR fusion gene by one-step RT-PCR is useful in the diagnosis of rhabdomyosarcomas (RMS) and that AChR-gamma is overexpressed in Chinese RMS patients. (PMID:18988640)
• We did not identify a clear difference in mutation spectrum of the CHRNG gene between lethal form and non-lethal forms of multiple pterygium syndromes (PMID:22167768)
• No mutations were found in CHRNG, CHRND and CHRNA1 genes of Indian families with Escobar syndrome. (PMID:23448903)
• Two siblings with Escobar syndrome caused by homozygous mutations of the CHRNG gene were identified. (PMID:25411939)
• Rare cases of congenital arthrogryposis multiplex caused by novel recurrent CHRNG mutations. (PMID:25608830)
• CHRNG mutations associated with interfamilial variability of the severity of the Escobar variant of multiple pterygium syndrome (PMID:27245440)
• A homozygous nonsense CHRNG variant c.136C>T (p.R46*), predicted to produce a truncated protein that leads to acetylcholine receptor deficiency was detected in a consanguineous Pakistani family with Escobar syndrome. (PMID:30461311)
• Our study contributes to further define the phenotypic spectrum of CHRNG-related nonlethal MPS, including muscle imaging features, which may be useful in distinguishing it from other diffuse arthrogryposis entities. (PMID:30868735)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	chrng	ENSDARG00000086647
mus_musculus	Chrng	ENSMUSG00000026253
rattus_norvegicus	Chrng	ENSRNOG00000077483

Paralogs (45): GABRA3 (ENSG00000011677), GABRA1 (ENSG00000022355), CHRNA3 (ENSG00000080644), GABRP (ENSG00000094755), CHRNA4 (ENSG00000101204), GLRA2 (ENSG00000101958), GABRE (ENSG00000102287), CHRNE (ENSG00000108556), GABRA4 (ENSG00000109158), GLRB (ENSG00000109738), GABRR2 (ENSG00000111886), GABRG2 (ENSG00000113327), CHRNB4 (ENSG00000117971), CHRNA2 (ENSG00000120903), CHRNA10 (ENSG00000129749), CHRND (ENSG00000135902), CHRNA1 (ENSG00000138435), GLRA3 (ENSG00000145451), GABRA6 (ENSG00000145863), GABRB2 (ENSG00000145864), GLRA1 (ENSG00000145888), GABRR1 (ENSG00000146276), CHRNB3 (ENSG00000147432), CHRNA6 (ENSG00000147434), HTR3B (ENSG00000149305), GABRA2 (ENSG00000151834), CHRNB2 (ENSG00000160716), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRB3 (ENSG00000166206), CHRFAM7A (ENSG00000166664), HTR3A (ENSG00000166736), CHRNA5 (ENSG00000169684), CHRNB1 (ENSG00000170175), CHRNA9 (ENSG00000174343), CHRNA7 (ENSG00000175344), HTR3C (ENSG00000178084), GABRG3 (ENSG00000182256), GABRR3 (ENSG00000183185), HTR3E (ENSG00000186038), HTR3D (ENSG00000186090), GABRA5 (ENSG00000186297), ZACN (ENSG00000186919), GABRD (ENSG00000187730), GABRQ (ENSG00000268089)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:87895) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 24 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal neuromuscular synapse morphology	2
abnormal miniature endplate potential	2
hindlimb paralysis	1
thin diaphragm muscle	1
abnormal motor neuron morphology	1
no spontaneous movement	1
dehydration	1
abnormal suckling behavior	1
trunk curl	1
cyanosis	1
decreased embryo size	1
abnormal breathing pattern	1
abnormal skin pigmentation	1
abnormal muscle physiology	1
abnormal diaphragm morphology	1
abnormal neuron morphology	1
abnormal skeletal muscle fiber morphology	1
increased motor neuron number	1
abnormal dendrite morphology	1
abnormal neurite morphology	1
increased variability of skeletal muscle fiber size	1
postnatal lethality, complete penetrance	1
neonatal lethality, complete penetrance	1
perinatal lethality, incomplete penetrance	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Tetronarce californica	P02710	99.1%	Diamond
Torpedo marmorata	P02711	99.1%	Diamond
Pan troglodytes	Q5IS77	98.4%	Diamond
Crocidura russula	P54248	94.0%	Diamond
Bos taurus	P04758	92.1%	Diamond
Caenorhabditis elegans	P54245	90.2%	Diamond
Gallus gallus	P09484	82.8%	Diamond
Caenorhabditis briggsae	Q60S81	80.6%	Diamond
Mustela putorius furo	Q19AE6	80.0%	Diamond
Xenopus laevis	P05376	71.1%	Diamond
Carassius auratus	P19370	69.1%	Diamond
Oncorhynchus mykiss	Q68RJ7	67.3%	Diamond
Drosophila melanogaster	P04755	48.3%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
CHRND	protein-coding	1144
TIGD1	protein-coding	200765
EFHD1	protein-coding	80303
EIF4E2	protein-coding	9470
MIR5001	ncRNA	100847037
PRSS56	protein-coding	646960
ECEL1	protein-coding	9427

Protein

Protein identifiers

Acetylcholine receptor subunit gamma — P07510 (reviewed: P07510)

All UniProt accessions (2): A0A6F7YAP6, P07510

UniProt curated annotations — full annotation on UniProt →

Function. After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

Subunit / interactions. Pentamer of two alpha chains, and one each of the beta, delta, and gamma (in immature muscle) or epsilon (in mature muscle) chains.

Subcellular location. Postsynaptic cell membrane. Cell membrane.

Disease relevance. Multiple pterygium syndrome, lethal type (LMPS) [MIM:253290] Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent. The disease is caused by variants affecting the gene represented in this entry. Multiple pterygium syndrome, Escobar variant (EVMPS) [MIM:265000] Non-lethal form of arthrogryposis multiplex congenita. It is an autosomal recessive condition characterized by excessive webbing (pterygia), congenital contractures (arthrogryposis), and scoliosis. Variable other features include intrauterine death, congenital respiratory distress, short stature, faciocranial dysmorphism, ptosis, low-set ears, arachnodactyly and cryptorchism in males. Congenital contractures are common and may be caused by reduced fetal movements at sensitive times of development. Possible causes of decreased fetal mobility include space constraints such as oligohydramnion, drugs, metabolic conditions or neuromuscular disorders including myasthenia gravis. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Gamma/CHRNG sub-subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P07510-1	1	yes
P07510-2	2

RefSeq proteins (1): NP_005190* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002394	Nicotinic_acetylcholine_rcpt	Family
IPR006029	Neurotrans-gated_channel_TM	Domain
IPR006201	Neur_channel	Family
IPR006202	Neur_chan_lig-bd	Domain
IPR018000	Neurotransmitter_ion_chnl_CS	Conserved_site
IPR036719	Neuro-gated_channel_TM_sf	Homologous_superfamily
IPR036734	Neur_chan_lig-bd_sf	Homologous_superfamily
IPR038050	Neuro_actylchol_rec	Homologous_superfamily

Pfam: PF02931, PF02932

Catalyzed reactions (Rhea)

• K(+)(in) = K(+)(out) (RHEA:29463)
• Na(+)(in) = Na(+)(out) (RHEA:34963)

UniProt features (16 total): transmembrane region 4, sequence variant 3, topological domain 2, glycosylation site 2, signal peptide 1, chain 1, disulfide bond 1, splice variant 1, sequence conflict 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P07510-F1	81.91	0.47

Human Protein Atlas

Protein class: Transporters, Transporter channels and pores, Predicted membrane proteins, Disease related genes, Potential drug targets, Human disease related genes, Congenital malformations, Other congenital malformations

Protein evidence: Evidence at protein level

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1)

Type	Positions
Disulfide bond	150–164

Glycosylation sites (2)

Type	Positions
N-linked (glcnac…) asparagine	52, 163

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 7; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

7 pathways:

ID	Pathway	Evidence
R-HSA-629587	Highly sodium permeable postsynaptic acetylcholine nicotinic receptors	curated
R-HSA-181431	Acetylcholine binding and downstream events	—
R-HSA-112316	Neuronal System	—
R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission	—
R-HSA-622327	Postsynaptic nicotinic acetylcholine receptors	—
R-HSA-622323	Presynaptic nicotinic acetylcholine receptors	—
R-HSA-112315	Transmission across Chemical Synapses	—

MSigDB gene sets: 380 (showing top): GOBP_MEMBRANE_DEPOLARIZATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_SYNAPTIC_TRANSMISSION_CHOLINERGIC, AP4_Q6, GOBP_MULTICELLULAR_ORGANISMAL_MOVEMENT, TAL1ALPHAE47_01, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_SKELETAL_MUSCLE_CONTRACTION, CAGCTG_AP4_Q5, GOBP_CELL_CELL_SIGNALING, MYOD_01, GOBP_MUSCLE_CONTRACTION, GOBP_REGULATION_OF_POSTSYNAPTIC_MEMBRANE_POTENTIAL, KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND

GO Biological Process (12): skeletal muscle contraction (GO:0003009), muscle contraction (GO:0006936), signal transduction (GO:0007165), chemical synaptic transmission (GO:0007268), monoatomic ion transmembrane transport (GO:0034220), membrane depolarization (GO:0051899), acetylcholine receptor signaling pathway (GO:0095500), monoatomic ion transport (GO:0006811), calcium ion transport (GO:0006816), synaptic transmission, cholinergic (GO:0007271), regulation of postsynaptic membrane potential (GO:0060078), excitatory postsynaptic potential (GO:0060079)

GO Molecular Function (8): channel activity (GO:0015267), acetylcholine receptor activity (GO:0015464), acetylcholine-gated monoatomic cation-selective channel activity (GO:0022848), transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential (GO:1904315), transmembrane signaling receptor activity (GO:0004888), monoatomic ion channel activity (GO:0005216), extracellular ligand-gated monoatomic ion channel activity (GO:0005230), protein binding (GO:0005515)

GO Cellular Component (6): plasma membrane (GO:0005886), acetylcholine-gated channel complex (GO:0005892), neuron projection (GO:0043005), synapse (GO:0045202), postsynaptic membrane (GO:0045211), membrane (GO:0016020)

Reactome top-level categories

6 top-level categories:

Category	Pathways
Acetylcholine binding and downstream events	2
Presynaptic nicotinic acetylcholine receptors	1
Postsynaptic nicotinic acetylcholine receptors	1
Transmission across Chemical Synapses	1
Neuronal System	1
Neurotransmitter receptors and postsynaptic signal transmission	1

GO top-level categories

43 GO namespaces:

Category	Terms
regulation of membrane potential	2
regulation of postsynaptic membrane potential	2
postsynaptic neurotransmitter receptor activity	2
striated muscle contraction	1
musculoskeletal movement	1
muscle system process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
anterograde trans-synaptic signaling	1
monoatomic ion transport	1
transmembrane transport	1
acetylcholine receptor activity	1
postsynaptic signal transduction	1
cellular response to acetylcholine	1
transport	1
metal ion transport	1
chemical synaptic transmission	1
chemical synaptic transmission, postsynaptic	1
passive transmembrane transporter activity	1
transmembrane signaling receptor activity	1
synaptic transmission, cholinergic	1
acetylcholine binding	1
excitatory extracellular ligand-gated monoatomic ion channel activity	1
ligand-gated monoatomic cation channel activity	1
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	1
transmitter-gated monoatomic ion channel activity	1
signaling receptor activity	1
monoatomic ion transmembrane transporter activity	1
channel activity	1
ligand-gated monoatomic ion channel activity	1
binding	1
membrane	1
cell periphery	1
monoatomic ion channel complex	1
plasma membrane signaling receptor complex	1
plasma membrane bounded cell projection	1
cell junction	1
synaptic membrane	1
postsynapse	1
cellular anatomical structure	1

Protein interactions and networks

STRING

showing 16 of 668 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CHRNG	RAPSN	Q13702	885
CHRNG	MUSK	O15146	771
CHRNG	DOK7	Q18PE1	655
CHRNG	COLQ	Q9Y215	648
CHRNG	AGRN	O00468	636
CHRNG	TNNI2	P48788	613
CHRNG	MYH2	Q9UKX2	567
CHRNG	TNNT3	P45378	556
CHRNG	COMMD6	Q7Z4G1	513
CHRNG	COL6A3	P12111	506
CHRNG	TPM2	P06468	503
CHRNG	UTRN	P46939	492
CHRNG	CAST	P20810	487
CHRNG	MYMK	A6NI61	485
CHRNG	MYOG	P15173	468
CHRNG	MYH3	P11055	468

IntAct

Human interaction partners of CHRNG in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

7 partners by confidence:

Partner	Interaction type	MIscore	Records
NOTCH2NLA	physical association	0.740	5
KRT31	physical association	0.670	4
KRTAP10-7	physical association	0.670	4
KRTAP10-8	physical association	0.670	4
KRTAP10-9	physical association	0.670	4
ACTL6B	physical association	0.400	1
KRTAP10-3	physical association	0.370	1

BioGRID (41 interactions; top human partners by supporting records): KRT31 (Two-hybrid; 4 records), KRTAP10-8 (Two-hybrid; 4 records), KRTAP10-9 (Two-hybrid; 4 records), NOTCH2NL (Two-hybrid; 4 records), KRTAP10-3 (Two-hybrid; 3 records), KRTAP10-7 (Two-hybrid; 3 records), ACTL6B (Affinity Capture-MS; 2 records), MDFI (Two-hybrid; 2 records), ADAMTSL4 (Two-hybrid), CHRNA1 (Co-fractionation), CYSRT1 (Two-hybrid), KRT34 (Two-hybrid), KRTAP1-1 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP12-3 (Two-hybrid)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
CHRNG	“form complex”	“Muscle-type nicotinic acetylcholine receptor complex, alpha1-beta1-delta-gamma”	binding

Ligand–receptor pairs (CellPhoneDB) (1)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

1 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
CHRNA1;CHRNB1;CHRND;CHRNG		Signaling by Choline acetyltransferase

Disease & clinical

Genetic variants

Variant evidence for CHRNG: 542 ClinVar records (69 pathogenic / likely pathogenic); 2 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

542 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	36
Likely pathogenic	33
Uncertain significance	113
Likely benign	272
Benign	29

Top pathogenic / likely-pathogenic (15)

Showing the 15 best-reviewed of 69 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
18342	NM_005199.5(CHRNG):c.753_754del (p.Val253fs)	Pathogenic	criteria provided, multiple submitters, no conflicts	19
449338	NM_005199.5(CHRNG):c.459dup (p.Val154fs)	Pathogenic	criteria provided, multiple submitters, no conflicts	17
419026	NM_005199.5(CHRNG):c.401_402del (p.Pro134fs)	Pathogenic	criteria provided, multiple submitters, no conflicts	11
195239	NM_005199.5(CHRNG):c.117dup (p.Asn40fs)	Pathogenic	criteria provided, multiple submitters, no conflicts	10
18337	NM_005199.5(CHRNG):c.715C>T (p.Arg239Cys)	Pathogenic	criteria provided, multiple submitters, no conflicts	9
18341	NM_005199.5(CHRNG):c.136C>T (p.Arg46Ter)	Pathogenic	criteria provided, multiple submitters, no conflicts	8
431955	NM_005199.5(CHRNG):c.397del (p.Ser133fs)	Pathogenic	criteria provided, multiple submitters, no conflicts	6
217751	NM_005199.5(CHRNG):c.428C>G (p.Pro143Arg)	Pathogenic	criteria provided, multiple submitters, no conflicts	4
1322085	NM_005199.5(CHRNG):c.56-1G>A	Pathogenic	criteria provided, multiple submitters, no conflicts	3
2506924	NM_005199.5(CHRNG):c.420G>A (p.Trp140Ter)	Pathogenic	criteria provided, multiple submitters, no conflicts	3
930743	NM_005199.5(CHRNG):c.1143G>A (p.Trp381Ter)	Pathogenic	criteria provided, multiple submitters, no conflicts	2
2859850	NM_005199.5(CHRNG):c.807dup (p.Gly270fs)	Pathogenic	criteria provided, multiple submitters, no conflicts	2
2961828	NM_005199.5(CHRNG):c.562C>T (p.Gln188Ter)	Pathogenic	criteria provided, multiple submitters, no conflicts	2
692272	NM_005199.5(CHRNG):c.710_711delinsAA (p.Ile237Lys)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	3
1804085	NM_005199.5(CHRNG):c.351-2A>G	Likely pathogenic	criteria provided, multiple submitters, no conflicts	3

Per-variant reference — Sugi Variant

Explore CHRNG’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 31 predictions of 937):

Position(s)	Effect	Δscore	Sites
2:232540132–232540133	donor_loss	1.0000	5
2:232542410–232542411	acceptor_gain	1.0000	2
2:232542421–232542422	acceptor_loss	1.0000	5
2:232542521–232542522	donor_loss	1.0000	4
2:232543100	donor_gain	1.0000
2:232544577	donor_gain	1.0000
2:232539830	donor_gain	0.9900
2:232540600–232540601	acceptor_loss	0.9900	6
2:232540712–232540713	donor_loss	0.9900	5
2:232541547	donor_gain	0.9900

AlphaMissense

1,014 missense substitutions predicted likely pathogenic (of 3,342 scored), across 283 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D84	8	0.984	0.993
F168	8	0.979	0.998
D160	8	0.964	0.979
N116	8	0.958	0.996
F157	8	0.942	0.993
F159	8	0.934	0.989
F122	8	0.932	0.995
N203	8	0.911	0.995
F287	8	0.910	0.980
D119	8	0.899	0.974
D196	8	0.853	0.964
D111	8	0.817	0.955
D473	8	0.805	0.910
F311	8	0.775	0.944
C150	7	0.997	0.999
W206	7	0.997	1.000
C164	7	0.996	0.999
W108	7	0.995	0.999
W89	7	0.988	0.998
F200	7	0.988	0.997

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Uterine Corpus Endometrial Carcinoma)

Disease associations

OMIM: gene MIM:100730 | disease phenotypes: MIM:265000, MIM:253290, MIM:617468, MIM:208150

GenCC curated gene-disease

3 curated gene-disease records:

Disease	Classification	Inheritance	Records
autosomal recessive multiple pterygium syndrome	Definitive	Autosomal recessive	3
transient neonatal myasthenia gravis	Strong	Autosomal recessive
lethal multiple pterygium syndrome	Strong	Autosomal recessive	2

ClinGen Gene-Disease Validity

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

1 validity classifications:

Disease	Classification	Inheritance
CHRNG-associated hypo-akinesia disorder of prenatal onset	Definitive	AR

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (9 panels, 9 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

9 panels:

Panel	Rating
Arthrogryposis	green
Clefting	green
Congenital myaesthenic syndrome	green
DDG2P	green
Fetal anomalies	green
Fetal hydrops	green
Hypotonic infant	green
Other rare neuromuscular disorders	green
Paediatric disorders	green

Mondo (7): autosomal recessive multiple pterygium syndrome (MONDO:0009926), lethal multiple pterygium syndrome (MONDO:0009668), scoliosis (MONDO:0005392), peripheral neuropathy (MONDO:0005244), arthrogryposis multiplex congenita (MONDO:0015168), fetal akinesia deformation sequence 1 (MONDO:0100101), transient neonatal myasthenia gravis (MONDO:0018326)

Orphanet (4): Autosomal recessive multiple pterygium syndrome (Orphanet:2990), Lethal multiple pterygium syndrome (Orphanet:33108), Arthrogryposis multiplex congenita (Orphanet:1037), Fetal akinesia deformation sequence (Orphanet:994)

HPO phenotypes

showing 60 of 122 phenotypes (HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000023	Inguinal hernia
HP:0000028	Cryptorchidism
HP:0000046	Small scrotum
HP:0000047	Hypospadias
HP:0000135	Hypogonadism
HP:0000157	Abnormality of the tongue
HP:0000160	Narrow mouth
HP:0000175	Cleft palate
HP:0000202	Orofacial cleft
HP:0000207	Triangular mouth
HP:0000218	High palate
HP:0000252	Microcephaly
HP:0000268	Dolichocephaly
HP:0000276	Long face
HP:0000286	Epicanthus
HP:0000307	Pointed chin
HP:0000316	Hypertelorism
HP:0000324	Facial asymmetry
HP:0000343	Long philtrum
HP:0000347	Micrognathia
HP:0000364	Hearing abnormality
HP:0000365	Hearing impairment
HP:0000369	Low-set ears
HP:0000405	Conductive hearing impairment
HP:0000457	Depressed nasal ridge
HP:0000465	Webbed neck
HP:0000470	Short neck
HP:0000476	Cystic hygroma
HP:0000486	Strabismus
HP:0000492	Abnormal eyelid morphology
HP:0000494	Downslanted palpebral fissures
HP:0000506	Telecanthus
HP:0000508	Ptosis
HP:0000689	Dental malocclusion
HP:0000766	Abnormal sternum morphology
HP:0000767	Pectus excavatum
HP:0000776	Congenital diaphragmatic hernia
HP:0000883	Thin ribs
HP:0000890	Long clavicle
HP:0000902	Rib fusion
HP:0000969	Edema
HP:0001040	Multiple pterygia
HP:0001059	Pterygium
HP:0001060	Axillary pterygium
HP:0001159	Syndactyly
HP:0001166	Arachnodactyly
HP:0001249	Intellectual disability
HP:0001288	Gait disturbance
HP:0001371	Flexion contracture
HP:0001373	Joint dislocation
HP:0001376	Limitation of joint mobility
HP:0001488	Bilateral ptosis
HP:0001508	Failure to thrive
HP:0001511	Intrauterine growth retardation
HP:0001537	Umbilical hernia
HP:0001558	Decreased fetal movement
HP:0001561	Polyhydramnios
HP:0001646	Abnormal aortic valve morphology
HP:0001760	Abnormal foot morphology

GWAS associations

2 associations:

Study	Trait	p-value
GCST010002_411	Refractive error	1e-123
GCST001858_8	Refractive error	5e-11

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D012600	Scoliosis	C05.116.900.800.875

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL1907588 (PROTEIN COMPLEX), CHEMBL2362997 (PROTEIN COMPLEX GROUP), CHEMBL4524133 (PROTEIN COMPLEX GROUP)

Drugs acting on a complex or family that includes this protein

Curated ChEMBL mechanism-of-action drugs whose target is a protein complex or family of ≤10 members that includes CHRNG — the drug acts on the assembly or class, not necessarily on this subunit alone.

14 drugs via a complex or family:

Drug	Target (ChEMBL)	Members	Max phase
ATRACURIUM BESYLATE	Muscle-type nicotinic acetylcholine receptor	5	4
CISATRACURIUM BESYLATE	Muscle-type nicotinic acetylcholine receptor	5	4
DECAMETHONIUM BROMIDE	Muscle-type nicotinic acetylcholine receptor	5	4
DOXACURIUM CHLORIDE	Muscle-type nicotinic acetylcholine receptor	5	4
GALLAMINE TRIETHIODIDE	Muscle-type nicotinic acetylcholine receptor	5	4
METOCURINE IODIDE	Muscle-type nicotinic acetylcholine receptor	5	4
MIVACURIUM CHLORIDE	Muscle-type nicotinic acetylcholine receptor	5	4
PANCURONIUM BROMIDE	Muscle-type nicotinic acetylcholine receptor	5	4
PIPECURONIUM BROMIDE	Muscle-type nicotinic acetylcholine receptor	5	4
RAPACURONIUM BROMIDE	Muscle-type nicotinic acetylcholine receptor	5	4
ROCURONIUM BROMIDE	Muscle-type nicotinic acetylcholine receptor	5	4
SUCCINYLCHOLINE CHLORIDE	Muscle-type nicotinic acetylcholine receptor	5	4
TUBOCURARINE CHLORIDE	Muscle-type nicotinic acetylcholine receptor	5	4
VECURONIUM BROMIDE	Muscle-type nicotinic acetylcholine receptor	5	4

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 260,190 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

10 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL894	BUPROPION	4	37,410
CHEMBL267936	MECAMYLAMINE	4	5,654
CHEMBL3	NICOTINE	4	187,543
CHEMBL56564	TROPISETRON	4	19,468
CHEMBL1076903	VARENICLINE	4	5,898
CHEMBL497939	CYTISINICLINE	3	2,806
CHEMBL2103881	DEXMECAMYLAMINE	3	19
CHEMBL134713	GTS-21	2	275
CHEMBL1172928	RADAFAXINE	2	1,085
CHEMBL504652	TC-2216	1	32

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: lgic — Nicotinic acetylcholine receptors (nACh)

Binding affinities (BindingDB)

52 measured of 70 human assays (71 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
(3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-INDOLE-3-CARBOXYLATE	KI	5.3 nM
(1R,9R)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one	EC50	11 nM
9-Chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one	EC50	28 nM
9-Bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one	EC50	31 nM
11,11-dimethyl-6-oxo-7-aza-11-azoniatricyclo[7.3.1.02,7]trideca-2,4-diene iodide	EC50	37 nM
9-Iodo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one	EC50	45 nM
(2R,4S)-2-(6-Iodo-pyridin-3-yl)-7-aza-bicyclo[2.2.1]heptane	IC50	160 nM
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-6-carboxamide	IC50	188 nM
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one	IC50	330 nM
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide	IC50	580 nM
(R)-4-chloro-N-(quinuclidin-3-yl)benzamide	KI	930 nM
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide	IC50	962 nM
3-(1H-Indole-3-carbonyloxy)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane	KI	3000 nM
CHEMBL342235	IC50	5330 nM
(2S,3S)-2-Biphenyl-4-yl-3,5,5-trimethylmorpholin-2-ol	IC50	5900 nM
(2S,3S)-2-(Naphthalen-1-yl)-3,5,5-trimethylmorpholin-2-ol	IC50	6600 nM
(+/-)2-(3,5-Dichlorophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	7200 nM
(+/-)2-(3,4-Dichlorophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	7200 nM
(2S,3S)-2-(3-Chlorophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	7600 nM
(2S,3S)-2-(3-Chlorophenyl)-5,5-dimethyl-3-propyl-morpholin-2-ol	IC50	10000 nM
CHEMBL140652	IC50	10100 nM
CHEMBL141954	IC50	10900 nM
(2S,3S)-2-(Naphthalen-2-yl)-3,5,5-trimethylmorpholin-2-ol	IC50	11000 nM
N-[1-{3-[4-(3-Amino-propylamino)-butylamino]-propylcarbamoyl}-2-(4-hydroxy-phenyl)-ethyl]-butyramide	IC50	11800 nM
CHEMBL139085	IC50	12600 nM
CHEMBL137909	IC50	13200 nM
(2S,3S)-2-(3-Chlorophenyl)-3-ethyl-5,5-dimethylmorpholin-2-ol	IC50	14000 nM
NSC_6442277	EC50	15000 nM
N-[(S)-1-(12-Amino-dodecylcarbamoyl)-2-(4-hydroxy-phenyl)-ethyl]-butyramide	IC50	15100 nM
CHEMBL140491	IC50	17200 nM
(2S,3S)-2-(3-Bromophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	18000 nM
(2S,3S)-2-(4-Chlorophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	19000 nM
(2S,3S)-3,5,5-Trimethyl-2-(4-methylphenyl)morpholin-2-ol	IC50	20000 nM
CHEMBL137820	IC50	22300 nM
(2S,3S)-2-(3,5-Difluorophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	23000 nM
(2S,3S)-2-(4-Methoxyphenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	25000 nM
CHEMBL141800	IC50	25300 nM
CHEMBL140056	IC50	25900 nM
(2R,3R)-2-(3-Chlorophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	28000 nM
CHEMBL342258	IC50	30700 nM
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	IC50	33000 nM
(2S,3S)-2-(3,4-Difluorophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	36000 nM
(2S,3S)-2-(4-Chlorophenyl)-3,4,5,5-tetramethylmorpholin-2-ol	IC50	43000 nM
(2S,3S)-2-(3-Methoxyphenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	49000 nM
(2S,3S)-2-(3-Chlorophenyl)-3,4,5,5-tetramethylmorpholin-2-ol	IC50	57000 nM
(2S,3S)-2-(4-Fluorophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	69000 nM
(2S,3S)-2-(3-Nitrophenyl)-3,5,5-trimethylmorpholin-2-ol	IC50	96000 nM
CHEMBL342483	IC50	104000 nM
CHEMBL141037	IC50	105000 nM
CHEMBL336882	IC50	110000 nM

ChEMBL bioactivities

83 potent at pChembl≥5 of 133 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.28	EC50	0.053	nM	EPIBATIDINE
8.82	IC50	1.5	nM	CHEMBL566050
8.70	IC50	2	nM	CHEMBL569465
8.57	IC50	2.7	nM	CHEMBL566208
8.41	IC50	3.9	nM	CHEMBL566886
8.24	IC50	5.7	nM	CHEMBL565844
8.24	IC50	5.8	nM	CHEMBL592854
8.19	IC50	6.5	nM	CHEMBL599846
8.12	IC50	7.6	nM	CHEMBL566001
8.04	IC50	9.2	nM	CHEMBL589250
8.01	IC50	9.8	nM	CHEMBL568140
8.00	IC50	10	nM	CHEMBL565396
7.96	EC50	11	nM	CYTISINICLINE
7.96	IC50	11	nM	CHEMBL566832
7.92	IC50	12	nM	CHEMBL566207
7.92	IC50	12	nM	CHEMBL565845
7.85	IC50	14	nM	CHEMBL566000
7.80	IC50	16	nM	CHEMBL603620
7.80	IC50	16	nM	CHEMBL578612
7.80	IC50	16	nM	CHEMBL567481
7.77	IC50	17	nM	CHEMBL578611
7.72	IC50	19	nM	CHEMBL596775
7.72	IC50	19	nM	CHEMBL599230
7.62	IC50	24	nM	CHEMBL578610
7.58	IC50	26	nM	CHEMBL605501
7.55	EC50	28	nM	CHEMBL64496
7.55	IC50	28	nM	CHEMBL566420
7.51	EC50	31	nM	CHEMBL305106
7.50	IC50	32	nM	CHEMBL576063
7.43	EC50	37	nM	CHEMBL181840
7.39	IC50	41	nM	CHEMBL598026
7.35	EC50	45	nM	CHEMBL62858
7.28	IC50	53	nM	CHEMBL589494
7.16	IC50	69	nM	CHEMBL565386
7.06	IC50	87	nM	CHEMBL580143
6.60	Ki	250	nM	CYTISINICLINE
6.52	IC50	300	nM	2(R)-MECAMYLAMINE
6.50	Ki	314	nM	CHEMBL59986
6.28	Ki	520	nM	CHEMBL196626
6.28	Ki	530	nM	CHEMBL1209305
6.24	Ki	580	nM	CHEMBL2057714
6.22	IC50	600	nM	DEXMECAMYLAMINE
6.19	Ki	650	nM	CHEMBL194204
6.10	IC50	790	nM	CHEMBL15998
5.99	Ki	1020	nM	CHEMBL1209070
5.83	Ki	1480	nM	NICOTINE
5.78	Ki	1680	nM	CHEMBL1209124
5.61	IC50	2430	nM	CHEMBL342483
5.52	Ki	3000	nM	CHEMBL111583
5.52	IC50	3000	nM	CHEMBL1812748

PubChem BioAssay actives

83 with measured affinity, of 504 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	246397: Change in membrane potential in TE-671 cells expressing acetylcholine neuromuscular receptors	ec50	0.0001	uM
2-(tert-butylamino)-1-(3,4-dichlorophenyl)pentan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0015	uM
2-(tert-butylamino)-1-(3-chlorophenyl)pentan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0020	uM
2-(tert-butylamino)-1-(3,4-dichlorophenyl)butan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0027	uM
2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0039	uM
2-(tert-butylamino)-1-(3-chloro-4-methylphenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0057	uM
2-(cyclopentylamino)-1-(3-methylphenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0058	uM
1-(3-bromophenyl)-2-(cyclopentylamino)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0065	uM
1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0076	uM
Bupropion	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0079	uM
2-(cyclopentylamino)-1-(3-methoxyphenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0092	uM
2-(tert-butylamino)-1-(3,4-dichlorophenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0098	uM
1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0100	uM
cytisinicline	246397: Change in membrane potential in TE-671 cells expressing acetylcholine neuromuscular receptors	ec50	0.0110	uM
2-(tert-butylamino)-1-(3-methylphenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0110	uM
1-(4-bromo-3-methylphenyl)-2-(tert-butylamino)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0120	uM
2-(tert-butylamino)-1-(4-methylphenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0120	uM
2-(tert-butylamino)-1-(4-chlorophenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0140	uM
2-[tert-butyl(methyl)amino]-1-(3-chlorophenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0160	uM
3-(tert-butylamino)-1-(3-chlorophenyl)-2-methylpropan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0160	uM
2-(tert-butylamino)-1-(3-methoxyphenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0160	uM
2-(tert-butylamino)-1-(3,5-dichlorophenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0170	uM
2-(cyclopentylamino)-1-(3-nitrophenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0190	uM
1-(3-bromophenyl)-2-piperidin-1-ylpropan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0190	uM
2-(tert-butylamino)-1-(3,4-difluorophenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0240	uM
2-(cyclopentylamino)-1-(3-fluorophenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0260	uM
1-(3-chlorophenyl)-2-piperidin-1-ylpropan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0280	uM
5-chloro-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one	246397: Change in membrane potential in TE-671 cells expressing acetylcholine neuromuscular receptors	ec50	0.0280	uM
5-bromo-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one	246397: Change in membrane potential in TE-671 cells expressing acetylcholine neuromuscular receptors	ec50	0.0310	uM
2-(tert-butylamino)-1-(3-fluorophenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0320	uM
11,11-dimethyl-7-aza-11-azoniatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one iodide	246397: Change in membrane potential in TE-671 cells expressing acetylcholine neuromuscular receptors	ec50	0.0370	uM
2-(tert-butylamino)-1-(3-nitrophenyl)propan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0410	uM
5-iodo-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one	246397: Change in membrane potential in TE-671 cells expressing acetylcholine neuromuscular receptors	ec50	0.0450	uM
1-(3-methylphenyl)-2-piperidin-1-ylpropan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0530	uM
2-(tert-butylamino)-1-thiophen-2-ylpropan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0690	uM
1-(3-methoxyphenyl)-2-piperidin-1-ylpropan-1-one	459717: Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0870	uM
(1R,2R,4S)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine	1179333: Antagonist activity at human alpha1beta1gammadelta nAChR	ic50	0.3000	uM
3-[[(2S)-azetidin-2-yl]methoxy]pyridine	1179333: Antagonist activity at human alpha1beta1gammadelta nAChR	ki	0.3140	uM
10-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene-4-carbonitrile	254522: Binding affinity to human Nicotinic acetylcholine receptor alpha-1-beta-gamma-delta expressed in HEK 293 cells using [3H]alpha-bungarotoxin	ki	0.5200	uM
N-[5-[2-[[(1R,5R,6S)-3-azabicyclo[3.2.1]octan-6-yl]oxy]phenyl]-3-pyridinyl]acetamide;hydrochloride	495032: Binding affinity to alpha-1-beta-gamma-delta nicotinic receptor	ki	0.5300	uM
1’-pyridin-3-ylspiro[1-azabicyclo[2.2.1]heptane-7,3’-pyrrolidine]	673332: Binding affinity to human muscle nAChR alpha1beta1gammadelta expressed in human TE-671 cells	ki	0.5800	uM
(1R,2S,4S)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine	1179333: Antagonist activity at human alpha1beta1gammadelta nAChR	ic50	0.6000	uM
1-(10-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-trien-4-yl)ethanone	254522: Binding affinity to human Nicotinic acetylcholine receptor alpha-1-beta-gamma-delta expressed in HEK 293 cells using [3H]alpha-bungarotoxin	ki	0.6500	uM
N-[(2S)-1-(12-aminododecylamino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]butanamide	225872: Antagonist activity at human muscle-type nAChR (embryonic muscle) expressed in TE671 cells; (end value).	ic50	0.7900	uM
(1R,5R,6S)-6-(2-pyridin-3-ylphenoxy)-3-azabicyclo[3.2.1]octane;hydrochloride	495032: Binding affinity to alpha-1-beta-gamma-delta nicotinic receptor	ki	1.0200	uM
Nicotine	495032: Binding affinity to alpha-1-beta-gamma-delta nicotinic receptor	ki	1.4800	uM
5-[2-[[(1R,5R,6S)-3-azabicyclo[3.2.1]octan-6-yl]oxy]phenyl]pyridin-3-ol;hydrochloride	495032: Binding affinity to alpha-1-beta-gamma-delta nicotinic receptor	ki	1.6800	uM
N-[(2S)-1-(12-aminododecylamino)-3-(3-hydroxyphenyl)-1-oxopropan-2-yl]butanamide	225872: Antagonist activity at human muscle-type nAChR (embryonic muscle) expressed in TE671 cells; (end value).	ic50	2.4300	uM
(8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 1H-indole-3-carboxylate	145855: In vitro Binding affinity towards alpha-1-beta-1-gamma-delta nAChR was determined	ki	3.0000	uM
5-[(1R,2S,3S,5S)-3-(4-chloro-3-methylphenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-3-phenyl-1,2-oxazole	610460: Antagonist activity against human muscle-type alpha1beta1gammadelta nAChR in TE671/RD cells assessed as inhibition of carbamylcholine induced 86Rb+ efflux	ic50	3.0000	uM

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, decreases methylation	2
aristolochic acid I	increases expression	1
CGP 52608	increases reaction, affects binding	1
licochalcone B	decreases expression	1
incobotulinumtoxinA	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Persistent Organic Pollutants	increases abundance, increases expression	1
Acetylcholine	affects binding, increases activity	1
Carmustine	decreases expression	1
Estradiol	increases expression	1
Pesticides	increases expression, increases abundance	1
Phthalic Acids	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Thiram	decreases expression	1
Valproic Acid	increases methylation	1

ChEMBL screening assays

67 unique, capped per target: 36 binding, 31 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1039312	Binding	Activity at alpha-1-beta-1-gamma-delta nAChR in human TE671 cells assessed as effect on membrane potential by FLIPR assay	SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. — *Bioorg Med Chem*
CHEMBL1068092	Functional	Antagonist activity at alpha-1-beta-1-gamma-delta nAChR receptor expressed in human TE671/RD cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. — *J Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 301 trials:

NCT	Phase	Status	Title
NCT00508066	Phase 4	COMPLETED	Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery
NCT00510575	Phase 4	COMPLETED	Surgical Outcomes Using Variable Rod Diameters in the Treatment of Idiopathic Scoliosis
NCT00768313	Phase 4	WITHDRAWN	Phase IV Comparing Rods of Yield Strengths to Correct Adolescent Idiopathic Scoliosis.
NCT00880607	Phase 4	COMPLETED	Intrathecal Morphine Versus Epidural Extended Release Morphine for Pediatric Patients Undergoing Spinal Fusion
NCT00958581	Phase 4	COMPLETED	Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
NCT01852747	Phase 4	TERMINATED	Comparison of Actifuse ABX and Local Bone in Spinal Surgery
NCT02464813	Phase 4	COMPLETED	Effect of Pregabalin on Immediate Post-operative and Longterm Pain
NCT02465099	Phase 4	TERMINATED	Posterior Spinal Fusion With Two Energy Dissection Techniques
NCT06540885	Phase 4	COMPLETED	A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery
NCT06616220	Phase 4	COMPLETED	Dexamethasone for ESPB in Pain Management After Pediatric Idiopathic Scoliosis Surgery
NCT06789016	Phase 4	COMPLETED	Dexmedetomidine for ESPB in Pain Management After Pediatric Idiopathic Scoliosis Surgery
NCT00380965	Phase 4	COMPLETED	Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
NCT00487981	Phase 4	TERMINATED	Spinal Cord Stimulation for Painful Diabetic Neuropathy
NCT00904202	Phase 4	COMPLETED	A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
NCT01192113	Phase 4	COMPLETED	Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)
NCT01373983	Phase 4	COMPLETED	Intrathecal Bolus Doses of Ziconotide
NCT01458015	Phase 4	TERMINATED	Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain
NCT02074267	Phase 4	COMPLETED	Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain
NCT02372149	Phase 4	UNKNOWN	IVIg for Demyelination in Diabetes Mellitus
NCT02670161	Phase 4	ENROLLING_BY_INVITATION	Quality Improvement and Practice Based Research in Neurology Using the EMR
NCT07022938	Phase 4	COMPLETED	Nutritional Supplement for Treating Chemotherapy Induced Neuropathy
NCT07025005	Phase 4	RECRUITING	Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
NCT00323752	Phase 3	COMPLETED	Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.
NCT00684112	Phase 3	COMPLETED	Analgesic Effects of Gabapentin After Scoliosis Surgery in Children
NCT00737997	Phase 3	COMPLETED	Effect of Early Morphine Administration on the Development of Acute Opioid Tolerance During Pediatric Scoliosis Surgery
NCT01103115	Phase 3	COMPLETED	Calcium + Vitamin D Supplementation for Low Bone Mass in Adolescent Idiopathic Scoliosis (AIS)
NCT01108211	Phase 3	COMPLETED	Improving Low Bone Mass With Vibration Therapy in Adolescent Idiopathic Scoliosis (AIS)
NCT01205256	Phase 3	COMPLETED	IRB-HSR# 14145 R,S Methadone: Analgesia and Pharmacokinetics in Adolescents Undergoing Scoliosis Correction
NCT02558010	Phase 3	COMPLETED	Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients
NCT03537612	Phase 3	TERMINATED	Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain
NCT00058071	Phase 3	COMPLETED	Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
NCT00125268	Phase 3	TERMINATED	Near Infrared Light for the Treatment of Painful Peripheral Neuropathy
NCT00195013	Phase 3	COMPLETED	Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy
NCT00232141	Phase 3	COMPLETED	Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy
NCT00264875	Phase 3	COMPLETED	Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
NCT00369564	Phase 3	COMPLETED	Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
NCT00471445	Phase 3	COMPLETED	Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
NCT00489411	Phase 3	COMPLETED	Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00710554	Phase 3	COMPLETED	A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia
NCT00711880	Phase 3	COMPLETED	A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.
NCT00713323	Phase 3	COMPLETED	A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.
NCT00713817	Phase 3	COMPLETED	A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain
NCT00775645	Phase 3	COMPLETED	S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
NCT00872352	Phase 3	UNKNOWN	Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients
NCT00998738	Phase 3	TERMINATED	Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
NCT01049217	Phase 3	TERMINATED	Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy
NCT01099449	Phase 3	COMPLETED	Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
NCT01288937	Phase 3	TERMINATED	A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
NCT01492920	Phase 3	WITHDRAWN	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
NCT01775449	Phase 3	COMPLETED	Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet
NCT02024191	Phase 3	UNKNOWN	The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy
NCT02217267	Phase 3	COMPLETED	Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain
NCT02294149	Phase 3	UNKNOWN	Vit D3 and Omega 3 in Chemo Induced Neuropathy
NCT02311907	Phase 3	COMPLETED	Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
NCT06071936	Phase 3	UNKNOWN	Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
NCT06071975	Phase 3	UNKNOWN	Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
NCT06071988	Phase 3	UNKNOWN	Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
NCT06072573	Phase 3	UNKNOWN	Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
NCT07287592	Phase 3	NOT_YET_RECRUITING	Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.
NCT00273598	Phase 2	COMPLETED	Comparing Two Instrumentation Systems for the Treatment of Adolescent Scoliosis

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for CHRNG across ~30M SureChEMBL compounds — explore on Sugi Predict.